HER-2 Positive Metastatic Breast Cancer
2 clinical trials · Condition
◉ Watch HER-2 Positive Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer (NCT00146042) | University of Michigan Rogel Cancer Center | 1999-03-01 |
Track HER-2 Positive Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.